Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

image
Business Standard
177 22
Business Standard

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

SI Reporter  |  Mumbai 

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.



According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

RECOMMENDED FOR YOU

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, Wockhardt and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard